Full Press Release Details
of options, Issue of Equity PDMR Dealing and Total Voting Rights
New York, 21 October 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"),
a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces
that it has allotted and issued total of 1,750,000 ordinary shares of 3 pence each ("New Ordinary Shares") credited
as fully paid; (i) in the case of 1,200,000 New Ordinary Shares at a price of 15 pence per share and; (ii) in the case of 550,000
New Ordinary Shares at a price of 35 pence per share in respect of the exercise of; (i) 1,200,000 options with an exercise price
of 15 pence; and (ii) 550,000 options with an exercise price of 35 pence held by Gabriele Cerrone, Executive Chairman of the Company.
The aggregate interests of Mr Cerrone in shares and voting rights accordingly increase by 1,750,000 shares to 66,055,668
representing 34.19% of the issued share capital. This is within the 1% increase threshold permitted pursuant to Note 11 to Rule
9 of the UK Takeover Code.
has been made for the 1,750,000 New Ordinary Shares to be admitted to trading on AIM ("Admission"), and dealings
are expected to commence on or around 27 October 2020. The New Ordinary Shares will rank pari passu with the Company's existing
conformity with DTR 5.6.1, the Company notifies that as at the date of this announcement, it has a single class of shares in issue
being Ordinary Shares and that following the issue of the New Ordinary Shares to be issued in connection with the conversion of
his loan notes, the total number of Ordinary Shares in issue will be 193,226,787. There are no Ordinary Shares held in treasury.
Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.
figure of 193,226,787 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator
for the calculations by which they will determine whether they are required to notify their interest in, or a change to their
interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Tiziana Life Sciences
Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and
development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib,
the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn's Disease and nasally
administered foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb)
in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune and inflammatory
diseases, such as Crohn's Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis
and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin
6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of
announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person who arranged the
release of this information is Keeren Shah, Finance Director of Tiziana.
| Gabriele Cerrone, Chairman and founder | +44 (0)20 7495 2379 |
| Cairn Financial Advisers LLP (Nominated adviser) | |
| Liam Murray / Jo Turner | +44 (0)20 7213 0880 |
| Optiva Securities Limited (Broker) | |
| Robert Emmet | +44 (0)20 3981 4173 |
and public disclosure of transactions by Persons Discharging Managerial Responsibilities ("PDMR") and persons closely
associated with them ("PCA")
| 1. | Details of PDMR / person closely associated | |
| a) | Name | Gabriele Cerrone |
| 2. | Reason for the notification | |
| a) | Position / status | Executive Chairman |
| b) | Initial notification /amendment | Initial notification |
| 3. | Details of the issuer | |
| a) | Name | Tiziana Life Sciences plc |
| b) | LEI | 213800CED47HI8PIOB36 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument | Ordinary Shares of 3p each |
| b) | Identification code of the Financial Instrument | ISIN for Tiziana Life Sciences plc: GB00BKWNZY55 |
| c) | Nature of the transaction | Exercise of options |
| d) | Price(s) and volume(s) | ||
| Price | Volume | ||
| 15p | 1,200,000 | ||
| 35p | 550,000 |
| f) | Date of the transaction | 20 October 2020 |
| g) | Place of the transaction | XLON |